Stay updated with breaking news from Ret Fusions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer.
Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.
Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.
Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.